Amicus Therapeutics Announces FDA Approval and Launch of
Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) Approved in ERT-Experienced Adults First and Only Two-Component Therapy for Eligible Adults...
Source: globenewswire.com
Stay updated with breaking news from Team Amicu. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) Approved in ERT-Experienced Adults First and Only Two-Component Therapy for Eligible Adults...
Pombiliti™ + Opfolda™ Approved in ERT-Experienced Adults First and Only Two-Component Therapy for Eligible Adults Living with Late-onset Pompe Disease Amicus Therapeutics to Host Conference...